News | December 30, 2022
Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US
All claims against the company in the litigation have now been dismissed.
All claims against the company in the litigation have now been dismissed.
According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million
Post the sale, Patel family has become the single largest promoter shareholder in the company
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Subscribe To Our Newsletter & Stay Updated
